343326-72-7

Upstream product

• 209223-33-6 (R)-(+)-2-oxo-3-tert-butoxycarbonylamino-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 209223-32-5 (R)-(-)-2-tert-butoxycarbonylamino-3-(2-nitrophenylamino)propionic acid 
• 1493-27-2 ortho-nitrofluorobenzene 
• 252209-91-9 (R)-(-)-2-oxo-3-tert-butoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 

Downstream Products

• 343326-73-8 (R)-(-)-1-tert-butylcarbonylmethyl-2-oxo-3-phenoxycarbonylamino-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepine 
• 209219-38-5 (R)-(-)-3-[3-(1-tert-butylcarbonylmethyl-2-oxo-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-3-yl]ureido]benzoic acid 
• 252209-85-1 (R)-(-)-2-[3-[3-(1-tert-butylcarbonylmethyl-2-oxo-5-cyclohexyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-3-yl)ureido]phenyl]-2-methylpropionic acid 

Relevant academic research and scientific papers

CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY

Conjugates are described herein where CCK2R targeting ligands are attached to an active moiety, such as therapeutic agent or an imaging agent, through a linker. The conjugates can be used in the detection, diagnosis, imaging and treatment of cancer.

Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same

Provided are calcium salts of a 1,5-benzodiazepine derivative represented by the following formula (I): (wherein, R1 represents a lower alkyl group, R2 represents a phenyl or cyclohexyl group, and Y represents a single bond or a lowe